[1] Liu Y, Hong Z,Yan F, et al. Association of estrogen receptor gene polymorphisms and primary biliary cirrhosis in a Chinese population:a case control study. Chin Med J(Engl), 2015, 128:3008-3014. [2] Boonstra K, Beuers U, Ponsioen C. Epidemiology of primary sclerasing cholangitis and primary biliary cirrhosis:a systematic review. Hepatology, 2012, 56: 1181-1188. [3] Carey E, Ali A, Lindor K. Primary biliary cirrhosis. Lancet, 2015, 386:1565-1575. [4] 王璐,韩英. 2018年美国肝病学会原发性胆汁性胆管炎实践指导.临床肝胆病,2018,34:2300-2304. [5] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with de-compensated cirrhosis. Hepatology, 2018, S0168 -8278:31966-31974. [6] Tabit C, Chung W, Hamburg N, et al. Endothelial dysfunction in diabetes mellitus:molecular mechanisms and clinical implications. Rev Endocr Metab Disord, 2010,11:61-74. [7] Samuel M, Carlo S, Lorenzo D, et al. Late-onset autoimmunity: the paradigm of primary biliary cirrhosis-a mini-review. Gerontology, 2008,54:193-201. [8] Atsushi T, Patrick S. Environmental basis of primary biliary cholangitis. Exp Biol Med, 2018, 243: 184-189. [9] Poupon R. Primary biliary cirrhosis:a 2010 update. Hepatology, 2010, 52:745-58. [10] Culp K, Fleming C, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc, 1982,57:365-370. [11] Gershwin M, Selmi C, Worman H, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1,032 patients. Hepatology, 2005, 42: 1194–1202. [12] Floreani A, Franceschet I, Cazzagon N, et al. Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol, 2015, 48:192-197. [13] Zhang L, Shi T, Shi X, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14 year cohort study. Hepatology, 2013,58:264-272. |